Skip to main content

Dimethyl Fumarate: A Review in Relapsing-Remitting MS

Drugs volume 79, pages 1965–1976 (2019)Cite this article

Abstract

Dimethyl fumarate (Tecfidera®) is approved for the treatment of relapsing forms of multiple sclerosis (MS). Based on evidence from the clinical trial and real-world settings, dimethyl fumarate is an effective treatment in this patient population, with benefits maintained over the longer term. In the pivotal, placebo-controlled phase III DEFINE and CONFIRM trials in adults with relapsing-remitting multiple sclerosis (RRMS), twice-daily dimethyl fumarate reduced clinical relapse and MRI measures of disease activity and improved some aspects of health-related quality of life (HR-QoL). Reduced disability progression was also observed with dimethyl fumarate in DEFINE. Results in predominantly East Asian patients (APEX trial) were reflective of those seen in DEFINE and CONFIRM. Dimethyl fumarate had an acceptable tolerability profile. The most common adverse events were flushing and gastrointestinal events, which were of mild or moderate severity and appear to be largely manageable. Thus twice-daily dimethyl fumarate remains an effective treatment option for use in patients with RRMS, with the convenience of oral administration.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4(1):43.

    PubMed  Article  Google Scholar 

  2. Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96–120.

    PubMed  Article  Google Scholar 

  3. National Multiple Sclerosis Society. MS. 2019. http://www.nationalmssociety.org. Accessed 13 Nov 2019.

  4. Linker RA, Chan A. Navigating choice in multiple sclerosis management. Neurol Res Pract. 2019. https://doi.org/10.1186/s42466-019-0005-5.

    Article  Google Scholar 

  5. Costello K, Kalb R. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence. 2014. http://www.nationalmssociety.org. Accessed 13 Nov 2019.

  6. Dobson R, Giovannoni G. Multiple sclerosis—a review. Eur J Neurol. 2019;26(1):27–40.

    CAS  PubMed  Article  Google Scholar 

  7. Kim W, Zandona ME, Kim SH, et al. Oral disease-modifying therapies for multiple sclerosis. J Clin Neurol. 2015;11(1):9–19.

    PubMed  PubMed Central  Article  Google Scholar 

  8. Biogen Inc. Tecfidera® (dimethyl fumarate) delayed-release capsules, for oral use: US prescribing information. 2017. http://www.dailymed.nlm.nih.gov. Accessed 13 Nov 2019.

  9. European Medicines Agency. Tecfidera® (dimethyl fumarate) gastro-resistant hard capsules: summary of product characteristics. 2014. http://www.ema.europa.eu. Accessed 13 Nov 2019.

  10. Burness CB, Deeks ED. Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis. CNS Drugs. 2014;28(4):373–87.

    CAS  PubMed  Article  Google Scholar 

  11. Deeks ED. Dimethyl fumarate: a review in relapsing-remitting MS. Drugs. 2016;76(2):243–54.

    CAS  PubMed  Article  Google Scholar 

  12. Yadav SK, Soin D, Ito K, et al. Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis. J Mol Med. 2019;97(4):463–72.

    CAS  PubMed  Article  Google Scholar 

  13. Diebold M, Sievers C, Bantug G, et al. Dimethyl fumarate influences innate and adaptive immunity in Multiple Sclerosis. J Autoimmun. 2018;86:39–50.

    CAS  PubMed  Article  Google Scholar 

  14. Kornberg MD, Bhargava P, Kim PM, et al. Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. Science. 2018;360(6387):449–53.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  15. Carlstrom KE, Ewing E, Granqvist M, et al. Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes. Nat Commun. 2019;10(1):3081.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  16. Breuer J, Herich S, Schneider-Hohendorf T, et al. Dual action by fumaric acid esters synergistically reduces adhesion to human endothelium. Mult Scler. 2017;24(14):1871–82.

    Article  CAS  Google Scholar 

  17. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098–107.

    CAS  PubMed  Article  Google Scholar 

  18. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087–97.

    CAS  PubMed  Article  Google Scholar 

  19. Gold R, Arnold DL, Bar-Or A, et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study. Mult Scler. 2017;23(2):253–65.

    CAS  PubMed  Article  Google Scholar 

  20. Viglietta V, Miller D, Bar-Or A, et al. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Ann Clin Transl Neurol. 2015;2(2):103–18.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  21. Kappos L, Giovannoni G, Gold R, et al. Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis. Eur J Neurol. 2015;22(4):664–71.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  22. Fernandez O, Giovannoni G, Fox RJ, et al. Efficacy and safety of delayed-release dimethyl fumarate for relapsing-remitting multiple sclerosis in prior interferon users: an integrated analysis of DEFINE and CONFIRM. Clin Ther. 2017;39(8):1671–9.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  23. Fox RJ, Gold R, Phillips JT, et al. Efficacy and tolerability of delayed-release dimethyl fumarate in Black, Hispanic, and Asian patients with relapsing-remitting multiple sclerosis: post hoc integrated analysis of DEFINE and CONFIRM. Neurol Ther. 2017;6(2):175–87.

    PubMed  PubMed Central  Article  Google Scholar 

  24. Gold R, Giovannoni G, Phillips JT, et al. Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS). Mult Scler. 2015;21(1):57–66.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  25. Bar-Or A, Gold R, Kappos L, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol. 2013;260(9):2297–305.

    CAS  PubMed  Article  Google Scholar 

  26. Hutchinson M, Fox RJ, Miller DH, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol. 2013;260(9):2286–96.

    CAS  PubMed  Article  Google Scholar 

  27. Gold R, Giovannoni G, Phillips JT, et al. Overall safety and efficacy through 10 years of treatment with delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis [abstract no. P1397 + poster]. Mult Scler. 2019;25(S2):772–3.

    Google Scholar 

  28. Giovannoni G, Gold R, Kappos L, et al. Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: integrated analysis of DEFINE and CONFIRM. Mult Scler J Exp Transl Clin. 2016. https://doi.org/10.1177/2055217316634111.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Arnold DL, Gold R, Kappos L, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 DEFINE study. J Neurol. 2014;261(9):1794–802.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  30. Miller DHF, Fox RJ, Phillips JT, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology. 2015;84(11):1145–52.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  31. Nakamura K, Mokliatchouk O, Arnold DL, et al. Effects of dimethyl fumarate on brain volume change in relapsing-remitting multiple sclerosis: a pooled analysis of the phase 3 DEFINE and CONFIRM studies [abstract no. P3.2-064]. Neurology. 2019;92(Suppl 15).

  32. Arnold DL, Gold R, Kappos L, et al. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. J Neurol. 2014;261(12):2429–37.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  33. Arnold DL, Fox RJ, Gold R, et al. MRI outcomes at seven years in relapsing-remitting multiple sclerosis patients treated with delayed-release dimethyl fumarate in DEFINE, CONFIRM, and ENDORSE [abstract no. S12.002]. Neurology. 2017;88:Suppl 16.

  34. Havrdova E, Giovannoni G, Gold R, et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol. 2017;24(5):726–33.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  35. Kappos L, Gold R, Arnold DL, et al. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler. 2014;20(2):243–52.

    PubMed  Article  CAS  Google Scholar 

  36. Kita M, Fox RJ, Phillips JT, et al. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Mult Scler. 2014;20(2):253–7.

    CAS  PubMed  Article  Google Scholar 

  37. Kita M, Fox RJ, Gold R, et al. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies. Clin Ther. 2014;36(12):1958–71.

    CAS  PubMed  Article  Google Scholar 

  38. Saida T, Yamamura T, Kondo T, et al. A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries. BMC Neurol. 2019;19(1):5.

    PubMed  PubMed Central  Article  Google Scholar 

  39. Kondo T, Kawachi I, Onizuka Y, et al. Efficacy of dimethyl fumarate in Japanese multiple sclerosis patients: interim analysis of randomized, double-blind APEX study and its open-label extension. Mult Scler J Exp Transl Clin. 2019. https://doi.org/10.1177/2055217319864974.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Mori M, Ohashi T, Onizuka Y, et al. Efficacy and safety of dimethyl fumarate in treatment-naive Japanese patients with multiple sclerosis: interim analysis of the randomized placebo-controlled study. Mult Scler J Exp Transl Clin. 2019. https://doi.org/10.1177/2055217319852727.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Lorscheider J, Benkert P, Lienert C, et al. Fingolimod vs. dimethyl fumarate in relapsing-remitting multiple sclerosis: propensity score matched comparison in a large observational data set [abstract no. P1145]. Mult Scler. 2017;23 (Suppl 3):601–2.

  42. Mallucci G, Annovazzi P, Miante S, et al. Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study. J Neurol. 2018;265(8):1850–9.

    CAS  PubMed  Article  Google Scholar 

  43. D’Amico E, Zanghi A, Callari G, et al. Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in relapsing-remitting multiple sclerosis: an Italian real-word multicenter experience. Ther Adv Neurol Disord. 2018. https://doi.org/10.1177/1756286418796404.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Pandey K, Giles K, Balashov K, et al. Safety and effectiveness of delayed-release dimethyl fumarate maintained over 4-years in multiple sclerosis patients treated in routine medical practice [abstract no. P649 + poster]. Mult Scler. 2019;25(S2):318–9.

    Google Scholar 

  45. Laplaud D-A, Casey R, Barbin L, et al. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. Neurology. 2019;93:e635–46.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  46. Kalincik T, Kubala Havrdova E, Horakova D, et al. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(4):458–68.

    PubMed  Article  Google Scholar 

  47. Giles K, Balashov K, Jones CC, et al. Real-world efficacy of delayed-release dimethyl fumarate in early multiple sclerosis: interim results from ESTEEM [abstract no. P595]. Mult Scler. 2018;24(S2):289–90.

    Google Scholar 

  48. Ontaneda D, Nicholas J, Carraro M, et al. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US. Mult Scler Relat Disord. 2019;27:101–11.

    PubMed  Article  Google Scholar 

  49. Nicholas J, Carraro M, Ontaneda D, et al. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide on the risk of relapse in MS patients switching from first-generation platform therapies in the US [abstract no. 374]. Neurology. 2018;90(Suppl 15).

  50. Cohan SL, Moses H, Calkwood J, et al. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: a multicenter retrospective observational study (STRATEGY). Mult Scler Relat Disord. 2018;22:27–34.

    PubMed  Article  Google Scholar 

  51. Braune S, Grimm S, van Hovell P, et al. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry. J Neurol. 2018;265(12):2980–92.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  52. Vollmer B, Ontaneda D, Bandyopadhyay A, et al. Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. Neurol Clin Pract. 2018;8(4):292–301.

    PubMed  PubMed Central  Article  Google Scholar 

  53. Mirabella M, Prosperini L, Lucchini M, et al. Safety and efficacy of dimethyl fumarate in multiple sclerosis: an Italian, multicenter, real-world study. CNS Drugs. 2018;32(10):963–70.

    CAS  PubMed  Article  Google Scholar 

  54. Miclea A, Leussink VI, Hartung HP, et al. Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study. J Neurol. 2016;263(8):1626–32.

    CAS  PubMed  Article  Google Scholar 

  55. Granqvist M, Burman J, Gunnarsson M, et al. Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS. Mult Scler. 2019. https://doi.org/10.1177/1352458519866600.

    Article  PubMed  Google Scholar 

  56. Sloane J, Phillips JT, Calkwood J, et al. Delayed-release dimethyl fumarate demonstrated no difference in clinical outcomes versus fingolimod in patients with relapsing-remitting multiple sclerosis: results from the real-world EFFECT study [abstract no. P1.362]. Neurology. 2018;90(Suppl):15.

  57. Vollmer BL, Nair KV, Sillau S, et al. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2019;6(2):252–62.

    CAS  PubMed  Google Scholar 

  58. Min J, Sloane J, Phillips JT, et al. Leveraging real-world evidence for comparative effectiveness: delayed-release dimethyl fumarate vs. fingolimod and glatiramer acetate in RRMS [abstract no. P016]. Mult Scler. 2018;24(Suppl 1):17–8.

  59. Lee A, Pike J, Edwards MR, et al. Quantifying the benefits of dimethyl fumarate over beta Interferon and glatiramer acetate therapies on work productivity outcomes in MS patients. Neurol Ther. 2017;6(1):79–90.

    PubMed  PubMed Central  Article  Google Scholar 

  60. Rock M, Pike J, Jones E, et al. Physician reported adherence in MS patients treated with injectable platform therapies versus delayed-release dimethyl fumarate: findings from a real-world cross-sectional study [abstract no. PND117]. Value Health. 2018;21(Suppl 3):S348.

  61. Rock M, Pike J, Jones E, et al. Reduced healthcare resource utilisation for patients treated with delayed release dimethyl fumarate vs injectable therapies: findings from a real-world cross-sectional study of MS patients [abstract no. PND79]. Value Health. 2018;21(Suppl 3):S342.

  62. Brochet B, Tourbah A, Castelnovo G, et al. Effectiveness of dimethyl fumarate on disease activity and patient-reported outcomes in French subjects with relapsing-remitting multiple sclerosis in the real-world: a subgroup analysis of PROTEC [abstract no. P1135]. Mult Scler. 2017;23(Suppl 3):594–5.

  63. Buron MD, Chalmer TA, Sellebjerg F, et al. Comparative effectiveness of teriflunomide and dimethyl fumarate: a nationwide cohort study. Neurology. 2019;92(16):e1811–20.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  64. Forsberg L, Kagstrom S, Leandersson A, et al. A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of dimethyl fumarate (IMSE 5) [abstract no. EP1682]. Mult Scler. 2017;23(Suppl 3):884–5.

  65. Moiola L, Esposito F, Di Cristinzi M, et al. Comparative effectiveness of dimethylfumarate and fingolimod in an Italian monocentric cohort of relapsing remitting multiple sclerosis [abstract no. 228]. Eur J Neurol. 2019;26(Suppl 1):677.

  66. Kresa-Reahl K, Repovic P, Robertson D, et al. Effectiveness of delayed-release dimethyl fumarate on clinical and patient-reported outcomes in patients with relapsing multiple sclerosis switching from glatiramer acetate: RESPOND, a prospective observational study. Clin Ther. 2018;40(12):2077–87.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  67. Ochi H, Niino M, Onizuka Y, et al. 72-week safety and tolerability of dimethyl fumarate in Japanese patients with relapsing-remitting multiple sclerosis: analysis of the randomised, double blind, placebo-controlled, phase III APEX study and its open-label extension. Adv Ther. 2018;35(10):1598–611.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  68. Phillips JT, Selmaj K, Gold R, et al. Clinical significance of gastrointestinal and flushing events in patients with delayed-release dimethyl fumarate. Int J MS Care. 2015;17(5):236–43.

    PubMed  PubMed Central  Article  Google Scholar 

  69. Phillips JT, Hutchinson M, Fox R, et al. Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: experiences of an international panel. Mult Scler Relat Disord. 2014;3(4):513–9.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  70. Fox EJ, Vasquez A, Grainger W, et al. Gastrointestinal tolerability of delayed-release dimethyl fumarate in a multicenter, open-label study of patients with relapsing forms of multiple sclerosis (MANAGE). Int J MS Care. 2016;18(1):9–18.

    PubMed  PubMed Central  Article  Google Scholar 

  71. Phillips JT, Erwin AA, Agrella S, et al. Consensus management of gastrointestinal events associated with delayed-release dimethyl fumarate: a DELPHI study. Neurol Ther. 2015;4(2):137–46.

    Article  Google Scholar 

  72. Koulinska I, Riester K, Chalkias S, et al. Effect of bismuth subsalicylate on gastrointestinal tolerability in healthy volunteers receiving oral delayed-release dimethyl fumarate: PREVENT, a randomized, multicenter, double-blind, placebo-controlled study. Clin Ther. 2018;40(12):2021-30.e1.

    Article  CAS  Google Scholar 

  73. O’Gorman J, Russell HK, Li J, et al. Effect of aspirin pretreatment or slow dose titration on flushing and gastrointestinal events in healthy volunteers receiving delayed-release dimethyl fumarate. Clin Ther. 2015;37(7):1402–19.

    PubMed  Article  CAS  Google Scholar 

  74. Rog D, Cader S, Harrower T, et al. Effect of aspirin on flushing in relapsing-remitting multiple sclerosis patients receiving delayed-release dimethyl fumarate [abstract no. P1246]. Mult Scler. 2016;22(Suppl 3):656–7.

  75. Mehta D, Miller C, Arnold DL, et al. Effect of dimethyl fumarate on lymphocytes in RRMS: implications for clinical practice. Neurology. 2019;92(15):e1724–38.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  76. Diebold M, Altersberger V, Decard BF, et al. A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence. Mult Scler. 2019;25(12):1682–5.

    PubMed  Article  Google Scholar 

  77. Garcia J, Chavez Baroni H, Dubessy AL, et al. Progressive multifocal leukoencephalopathy in a patient treated by dimethyl fumarate for multiple sclerosis with no lymphopenia but exhausted T lymphocyte subpopulations [abstract no. P1042]. Mult Scler J. 2019;25(Suppl 2):556.

  78. Baharnoori M, Gonzalez CT, Chua A, et al. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count. Mult Scler Relat Disord. 2018;20:51–7.

    CAS  PubMed  Article  Google Scholar 

  79. Gold R, Schlegel E, Elias-Hamp B, et al. Incidence and mitigation of gastrointestinal events in patients with relapsing-remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE). Ther Adv Neurol Disord. 2018. https://doi.org/10.1177/1756286418768775.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Min J, Cohan S, Alvarez E, et al. Real-world characterization of dimethyl fumarate-related gastrointestinal events in multiple sclerosis: management strategies to improve persistence on treatment and patient outcomes. Neurol Ther. 2019;8:109–19.

    PubMed  PubMed Central  Article  Google Scholar 

  81. Sejbaek T, Nybo M, Petersen T, et al. Real-life persistence and tolerability with dimethyl fumarate. Mult Scler Relat Disord. 2018;24:42–6.

    PubMed  Article  Google Scholar 

  82. Prosperini L, Lanzillo R, Fantozzi R, et al. A multi-centre observational analysis of persistence to treatment in the new MS era: the RESPECT study [abstract no. EP1792]. Mult Scler. 2017;23(Suppl 3):945–6.

  83. Pardo G, Jones DE. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol. 2017;264(12):2351–74.

    PubMed  PubMed Central  Article  Google Scholar 

  84. Eagle T, Stuart F, Chua AS, et al. Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis. Mult Scler Relat Disord. 2017;18:196–201.

    PubMed  Article  Google Scholar 

  85. Mayer L, Fink MK, Sammarco C, et al. Management strategies to facilitate optimal outcomes for patients treated with delayed-release dimethyl fumarate. Drug Saf. 2018;41(4):347–56.

    CAS  PubMed  Article  Google Scholar 

  86. Scolding N, Barnes D, Cader S, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015;15(4):273–9.

    PubMed  Article  Google Scholar 

  87. National Institute for Health and Care Excellence. Dimethyl fumarate for treating relapsing-remitting multiple sclerosis. 2014. http://www.nice.org.uk/guidance/ta320. Accessed 13 Nov 2019.

  88. Chan A, Cutter G, Fox RJ, et al. Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison. J Comp Eff Res. 2017;6(4):313–23.

    PubMed  Article  Google Scholar 

  89. Hutchinson M, Fox RJ, Havrdova E, et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr Med Res Opin. 2014;30(4):613–27.

    CAS  PubMed  Article  Google Scholar 

  90. Cutter G, Sormani MP, Betts M, et al. Comparative effectiveness of delayed-release dimethyl fumarate vs. other disease-modifying therapies in patients with multiple sclerosis: a network meta-analysis of real-world evidence [abstract no. P1394 + poster]. Mult Scler. 2019;25(S2):770.

    Google Scholar 

  91. Zagmutt FJ, Carroll CA. Meta-analysis of adverse events in recent randomized clinical trials for dimethyl fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis. Int J Neurosci. 2015;125(11):798–807.

    CAS  PubMed  Article  Google Scholar 

  92. Freedman MS, Montalban X, Miller AE, et al. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: assessing absolute differences using a number needed to treat analysis. Mult Scler Relat Disord. 2016;10:204–12.

    PubMed  Article  Google Scholar 

  93. Nixon R, Bergvall N, Tomic D, et al. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis. Adv Ther. 2014;31(11):1134–54.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  94. Fox RJ, Chan A, Zhang A, et al. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis. Curr Med Res Opin. 2017;33(2):175–83.

    CAS  PubMed  Article  Google Scholar 

  95. Biogen Inc. Vumerity™ (diroximel fumarate) delayed-release capsules, for oral use. 2019. http://www.vumerity.com. Accessed 13 Nov 2019.

  96. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777–88.

    PubMed  PubMed Central  Article  Google Scholar 

Download references

Acknowledgements

During the review process, the manufacturer of dimethyl fumarate (Biogen) was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Hannah A. Blair

Authors
  1. Hannah A. Blair
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hannah A. Blair.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

Hannah Blair is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.

Additional information

Enhanced material for this Adis Drug Evaluation can be found at https://doi.org/10.6084/m9.figshare.10294838.

The manuscript was reviewed by:M.Diebold, Neurologic Clinic & Policlinic, University Hospital & University of Basel, Basel, Switzerland; M. S. Freedman, University of Ottawa & the Ottawa Hospital Research Institute, Ottawa, ON, Canada; H.–P. Hartung, Department of Neurology, Heinrich-Heine University, Dusseldorf, Germany; L.Kappos, Neurologic Clinic & Policlinic, University Hospital & University of Basel, Basel, Switzerland.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Blair, H.A. Dimethyl Fumarate: A Review in Relapsing-Remitting MS. Drugs 79, 1965–1976 (2019). https://doi.org/10.1007/s40265-019-01229-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-019-01229-3